Review



retinal microvascular endothelial cells hrmecs  (Innoprot Inc)


Bioz Verified Symbol Innoprot Inc is a verified supplier
Bioz Manufacturer Symbol Innoprot Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Innoprot Inc retinal microvascular endothelial cells hrmecs
    Retinal Microvascular Endothelial Cells Hrmecs, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 93/100, based on 48 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/retinal microvascular endothelial cells hrmecs/product/Innoprot Inc
    Average 93 stars, based on 48 article reviews
    retinal microvascular endothelial cells hrmecs - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    93
    Innoprot Inc retinal microvascular endothelial cells hrmecs
    Retinal Microvascular Endothelial Cells Hrmecs, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/retinal microvascular endothelial cells hrmecs/product/Innoprot Inc
    Average 93 stars, based on 1 article reviews
    retinal microvascular endothelial cells hrmecs - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    94
    Angio-Proteomie human retinal microvascular endothelial cells hrmecs angio proteomie
    Human Retinal Microvascular Endothelial Cells Hrmecs Angio Proteomie, supplied by Angio-Proteomie, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human retinal microvascular endothelial cells hrmecs angio proteomie/product/Angio-Proteomie
    Average 94 stars, based on 1 article reviews
    human retinal microvascular endothelial cells hrmecs angio proteomie - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    90
    ScienCell human retinal microvascular endothelial cells (hrmecs)
    Effect of ranibizumab on the viability of adult retinal pigment epithelial 19 cells and human retinal <t>microvascular</t> <t>endothelial</t> cells. Cell viability was assessed using the Cell Counting Kit-8 assay ( n = 3, independent experiments). A: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on adult retinal pigment epithelial 19 (ARPE-19) cell viability; B: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on human retinal microvascular endothelial cell (HRMEC) viability. All results are expressed as the mean ± SD. d P < 0.0001. 1 P vs 24 hour group. 2 P vs 48 hour group. NC: Untreated group.
    Human Retinal Microvascular Endothelial Cells (Hrmecs), supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human retinal microvascular endothelial cells (hrmecs)/product/ScienCell
    Average 90 stars, based on 1 article reviews
    human retinal microvascular endothelial cells (hrmecs) - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Procell Inc human retinal microvascular endothelial cells (hrmecs)
    Effect of ranibizumab on the viability of adult retinal pigment epithelial 19 cells and human retinal <t>microvascular</t> <t>endothelial</t> cells. Cell viability was assessed using the Cell Counting Kit-8 assay ( n = 3, independent experiments). A: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on adult retinal pigment epithelial 19 (ARPE-19) cell viability; B: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on human retinal microvascular endothelial cell (HRMEC) viability. All results are expressed as the mean ± SD. d P < 0.0001. 1 P vs 24 hour group. 2 P vs 48 hour group. NC: Untreated group.
    Human Retinal Microvascular Endothelial Cells (Hrmecs), supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human retinal microvascular endothelial cells (hrmecs)/product/Procell Inc
    Average 90 stars, based on 1 article reviews
    human retinal microvascular endothelial cells (hrmecs) - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    93
    Innoprot Inc primary human retinal microvascular endothelial cells hrmecs
    Effect of ranibizumab on the viability of adult retinal pigment epithelial 19 cells and human retinal <t>microvascular</t> <t>endothelial</t> cells. Cell viability was assessed using the Cell Counting Kit-8 assay ( n = 3, independent experiments). A: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on adult retinal pigment epithelial 19 (ARPE-19) cell viability; B: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on human retinal microvascular endothelial cell (HRMEC) viability. All results are expressed as the mean ± SD. d P < 0.0001. 1 P vs 24 hour group. 2 P vs 48 hour group. NC: Untreated group.
    Primary Human Retinal Microvascular Endothelial Cells Hrmecs, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary human retinal microvascular endothelial cells hrmecs/product/Innoprot Inc
    Average 93 stars, based on 1 article reviews
    primary human retinal microvascular endothelial cells hrmecs - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    90
    Cell Systems Corporation human retinal microvascular endothelial cells (hrmecs)
    Effect of ranibizumab on the viability of adult retinal pigment epithelial 19 cells and human retinal <t>microvascular</t> <t>endothelial</t> cells. Cell viability was assessed using the Cell Counting Kit-8 assay ( n = 3, independent experiments). A: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on adult retinal pigment epithelial 19 (ARPE-19) cell viability; B: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on human retinal microvascular endothelial cell (HRMEC) viability. All results are expressed as the mean ± SD. d P < 0.0001. 1 P vs 24 hour group. 2 P vs 48 hour group. NC: Untreated group.
    Human Retinal Microvascular Endothelial Cells (Hrmecs), supplied by Cell Systems Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human retinal microvascular endothelial cells (hrmecs)/product/Cell Systems Corporation
    Average 90 stars, based on 1 article reviews
    human retinal microvascular endothelial cells (hrmecs) - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Cell Systems Corporation human retinal microvascular endothelial cells hrmecs
    Effect of ranibizumab on the viability of adult retinal pigment epithelial 19 cells and human retinal <t>microvascular</t> <t>endothelial</t> cells. Cell viability was assessed using the Cell Counting Kit-8 assay ( n = 3, independent experiments). A: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on adult retinal pigment epithelial 19 (ARPE-19) cell viability; B: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on human retinal microvascular endothelial cell (HRMEC) viability. All results are expressed as the mean ± SD. d P < 0.0001. 1 P vs 24 hour group. 2 P vs 48 hour group. NC: Untreated group.
    Human Retinal Microvascular Endothelial Cells Hrmecs, supplied by Cell Systems Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human retinal microvascular endothelial cells hrmecs/product/Cell Systems Corporation
    Average 90 stars, based on 1 article reviews
    human retinal microvascular endothelial cells hrmecs - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Olaf Pharmaceuticals human retinal microvascular endothelial cells hrmecs
    Effect of ranibizumab on the viability of adult retinal pigment epithelial 19 cells and human retinal <t>microvascular</t> <t>endothelial</t> cells. Cell viability was assessed using the Cell Counting Kit-8 assay ( n = 3, independent experiments). A: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on adult retinal pigment epithelial 19 (ARPE-19) cell viability; B: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on human retinal microvascular endothelial cell (HRMEC) viability. All results are expressed as the mean ± SD. d P < 0.0001. 1 P vs 24 hour group. 2 P vs 48 hour group. NC: Untreated group.
    Human Retinal Microvascular Endothelial Cells Hrmecs, supplied by Olaf Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human retinal microvascular endothelial cells hrmecs/product/Olaf Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    human retinal microvascular endothelial cells hrmecs - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    Effect of ranibizumab on the viability of adult retinal pigment epithelial 19 cells and human retinal microvascular endothelial cells. Cell viability was assessed using the Cell Counting Kit-8 assay ( n = 3, independent experiments). A: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on adult retinal pigment epithelial 19 (ARPE-19) cell viability; B: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on human retinal microvascular endothelial cell (HRMEC) viability. All results are expressed as the mean ± SD. d P < 0.0001. 1 P vs 24 hour group. 2 P vs 48 hour group. NC: Untreated group.

    Journal: World Journal of Diabetes

    Article Title: Effect of ranibizumab on diabetic retinopathy via the vascular endothelial growth factor/STAT3/glial fibrillary acidic protein pathway

    doi: 10.4239/wjd.v16.i5.99473

    Figure Lengend Snippet: Effect of ranibizumab on the viability of adult retinal pigment epithelial 19 cells and human retinal microvascular endothelial cells. Cell viability was assessed using the Cell Counting Kit-8 assay ( n = 3, independent experiments). A: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on adult retinal pigment epithelial 19 (ARPE-19) cell viability; B: Effect of ranibizumab (0 mg/mL, 0.0625 mg/mL, 0.125 mg/mL, or 025 mg/mL) treatment on human retinal microvascular endothelial cell (HRMEC) viability. All results are expressed as the mean ± SD. d P < 0.0001. 1 P vs 24 hour group. 2 P vs 48 hour group. NC: Untreated group.

    Article Snippet: Human retinal microvascular endothelial cells (HRMECs) and primary human retinal endothelial cells were purchased from ScienCell (Carlsbad, CA, United States) and cultured in a low-glucose (5.5 mmol/L) primary endothelial cell culture medium (ScienCell, Wuhan, Hubei Province, China) in a humidified atmosphere containing 50 mL/L carbon dioxide at 37 °C.

    Techniques: Cell Counting

    mRNA expression of vascular endothelial growth factor, interleukin 6, cluster of differentiation 18, intercellular adhesion molecule, tumor necrosis factor alpha, and signal transducer and activator of transcription 3 in adult retinal pigment epithelial 19 cells and human retinal microvascular endothelial cells. Untreated (NC) (5.5 mmol/L glucose), NC + ranibizumab (5.5 mmol/L glucose + 0.125 mg/mL ranibizumab), high glucose (Hg) (25 mmol/L glucose), and Hg + ranibizumab (25 mmol/L glucose + 0.125 mg/mL ranibizumab). A: Ratios of the mRNA expression of vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), cluster of 18 differentiation (CD18), intercellular adhesion molecule (ICAM), tumor necrosis factor alpha (TNF-α), and signal transducer and activator of transcription 3 (STAT3) in different adult retinal pigment epithelial 19 (ARPE-19) groups; B: Ratios of mRNA expression of VEGF, IL-6, CD18, ICAM, TNF-α, and STAT3 in different human retinal microvascular endothelial cell (HRMEC) groups. All results are expressed as the mean ± SD. a P < 0.05. b P < 0.01. 1 P vs NC group. 2 P vs Hg group.

    Journal: World Journal of Diabetes

    Article Title: Effect of ranibizumab on diabetic retinopathy via the vascular endothelial growth factor/STAT3/glial fibrillary acidic protein pathway

    doi: 10.4239/wjd.v16.i5.99473

    Figure Lengend Snippet: mRNA expression of vascular endothelial growth factor, interleukin 6, cluster of differentiation 18, intercellular adhesion molecule, tumor necrosis factor alpha, and signal transducer and activator of transcription 3 in adult retinal pigment epithelial 19 cells and human retinal microvascular endothelial cells. Untreated (NC) (5.5 mmol/L glucose), NC + ranibizumab (5.5 mmol/L glucose + 0.125 mg/mL ranibizumab), high glucose (Hg) (25 mmol/L glucose), and Hg + ranibizumab (25 mmol/L glucose + 0.125 mg/mL ranibizumab). A: Ratios of the mRNA expression of vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), cluster of 18 differentiation (CD18), intercellular adhesion molecule (ICAM), tumor necrosis factor alpha (TNF-α), and signal transducer and activator of transcription 3 (STAT3) in different adult retinal pigment epithelial 19 (ARPE-19) groups; B: Ratios of mRNA expression of VEGF, IL-6, CD18, ICAM, TNF-α, and STAT3 in different human retinal microvascular endothelial cell (HRMEC) groups. All results are expressed as the mean ± SD. a P < 0.05. b P < 0.01. 1 P vs NC group. 2 P vs Hg group.

    Article Snippet: Human retinal microvascular endothelial cells (HRMECs) and primary human retinal endothelial cells were purchased from ScienCell (Carlsbad, CA, United States) and cultured in a low-glucose (5.5 mmol/L) primary endothelial cell culture medium (ScienCell, Wuhan, Hubei Province, China) in a humidified atmosphere containing 50 mL/L carbon dioxide at 37 °C.

    Techniques: Expressing

    Expression of glial fibrillary acidic protein, signal transducer and activator of transcription 3 (STAT3), and phosphorylated STAT3 proteins in adult retinal pigment epithelial 19 cells and human retinal microvascular endothelial cells. Untreated (NC) (5.5 mmol/L glucose), NC + ranibizumab (5.5 mmol/L glucose + 0.125 mg/mL ranibizumab), high glucose (Hg) (25 mmol/L glucose), and Hg + ranibizumab (25 mmol/L glucose + 0.125 mg/mL ranibizumab). A: Expression of glial fibrillary acidic protein (GFAP), signal transducer and activator of transcription 3 (STAT3), and phosphorylated STAT3 (pSTAT3) proteins in adult retinal pigment epithelial 19 (ARPE-19) cells were detected by Western blot analysis; B: Expression of GFAP, STAT3, and pSTAT3 proteins in human retinal microvascular endothelial cells (HRMECs) were detected by Western blot analysis; C: Ratios of GFAP, STAT3, and pSTAT3 protein expression levels in different groups of ARPE-19 cells; D: Ratios of GFAP, STAT3, and pSTAT3 protein expression levels in different groups of HRMECs. All results are expressed as the mean ± SD. a P < 0.05. b P < 0.01. 1 P vs NC group. 2 P vs Hg group.

    Journal: World Journal of Diabetes

    Article Title: Effect of ranibizumab on diabetic retinopathy via the vascular endothelial growth factor/STAT3/glial fibrillary acidic protein pathway

    doi: 10.4239/wjd.v16.i5.99473

    Figure Lengend Snippet: Expression of glial fibrillary acidic protein, signal transducer and activator of transcription 3 (STAT3), and phosphorylated STAT3 proteins in adult retinal pigment epithelial 19 cells and human retinal microvascular endothelial cells. Untreated (NC) (5.5 mmol/L glucose), NC + ranibizumab (5.5 mmol/L glucose + 0.125 mg/mL ranibizumab), high glucose (Hg) (25 mmol/L glucose), and Hg + ranibizumab (25 mmol/L glucose + 0.125 mg/mL ranibizumab). A: Expression of glial fibrillary acidic protein (GFAP), signal transducer and activator of transcription 3 (STAT3), and phosphorylated STAT3 (pSTAT3) proteins in adult retinal pigment epithelial 19 (ARPE-19) cells were detected by Western blot analysis; B: Expression of GFAP, STAT3, and pSTAT3 proteins in human retinal microvascular endothelial cells (HRMECs) were detected by Western blot analysis; C: Ratios of GFAP, STAT3, and pSTAT3 protein expression levels in different groups of ARPE-19 cells; D: Ratios of GFAP, STAT3, and pSTAT3 protein expression levels in different groups of HRMECs. All results are expressed as the mean ± SD. a P < 0.05. b P < 0.01. 1 P vs NC group. 2 P vs Hg group.

    Article Snippet: Human retinal microvascular endothelial cells (HRMECs) and primary human retinal endothelial cells were purchased from ScienCell (Carlsbad, CA, United States) and cultured in a low-glucose (5.5 mmol/L) primary endothelial cell culture medium (ScienCell, Wuhan, Hubei Province, China) in a humidified atmosphere containing 50 mL/L carbon dioxide at 37 °C.

    Techniques: Expressing, Western Blot